Trial Profile
Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Pharmacodynamics; Proof of concept
- Sponsors Quest PharmaTech
- 04 Jun 2020 According to a Quest PharmaTech media release, oregovomab Phase 3 clinical trial FLORA-5, is based on this study.
- 04 Jun 2020 According to a Quest PharmaTech media release, data were recently published (Gynecol Oncol. 2020 Mar;156(3):523-529).
- 24 Mar 2020 According to an OncoQuest media release, results from this trial were published in Cancer Immunology, Immunotherapy.